Management Biography
Janet L. Dally has over 25 years of experience in the biotechnology, pharmaceutical, and medical technology industries as an investor relations advisor, healthcare fund analyst, business development, medical device marketing manager, and microbiologist. She is an active advocate for the biotechnology industry. From 2010 to 2022, Ms. Dally hosted a leading annual cancer immunotherapy conference for the investment community and industry.
Before founding MaidStone Life Sciences, Ms. Dally was a senior partner at MD Becker Partners. Prior to this, she was president of MontRidge, LLC, a boutique investor relations and strategic consulting firm specializing in the life science industry. During her tenure at these firms, Ms. Dally built meaningful relationships with the executive management of life science clients and the U.S. and European investment communities, resulting in increased institutional ownership, diversified shareholder base, sell-side analyst coverage, enhanced valuation, product acquisition, and successful financing.
Ms. Dally previously was vice president of investor relations at Burns McClellan, a life sciences communication firm. She was a buy-side analyst for six years for the Merrill Lynch Healthcare Fund, evaluating and recommending biotechnology, pharmaceutical, medical device, diagnostic, and healthcare services firms. She has held executive positions in strategic planning, business development, licensing, and mergers and acquisitions at Sterling Drug and Forest Laboratories.
In 2023, she joined FORCE Family Office as Director of Healthcare.
Ms. Dally was appointed to the Douglass Residential College Advisory Board (Rutgers University) and advisor to Springboard Enterprises.
Ms. Dally has an M.B.A. from the Tepper School of Business, Carnegie Mellon University, an M.S. in Microbiology from Wagner College, and a B.S. in Medical Technology from Rutgers University.